NBIX - Neurocrine Biosciences and Sentia Medical ink research collaboration agreement

Neurocrine Biosciences (NBIX) and Sentia Medical Sciences have entered into a research collaboration to discover novel, long-acting corticotropin-releasing factor ((CRF)) receptor antagonist peptide therapeutics.The collaboration will leverage Sentia’s proprietary peptide-based platform and Neurocrine’s drug development expertise in CRF biology to develop and commercialize medicines with the potential to treat a variety of hypothalamic-pituitary-adrenal ((HPA)) axis modulated diseases.Under the terms of the agreement, Sentia will provide to Neurocrine an exclusive license to existing preclinical CRF receptor antagonist peptide compounds.Sentia will receive an up-front payment and committed research funding from Neurocrine to support discovery efforts.The company is eligible to receive milestone and royalty payments based on products developed from the collaboration.Further financial details of the deal were not disclosed.

For further details see:

Neurocrine Biosciences and Sentia Medical ink research collaboration agreement